Article Text

other Versions

PDF
Topical Chemotherapy for OSSN : Current Status
  1. Ricardo Sepulveda1,
  2. Jacob Pe’er2,
  3. Edoardo Midena3,
  4. Stefan Seregard4,
  5. Harminder Dua5,
  6. Arun D Singh6,*
  1. 1 Cole Eye Institute, Cleveland Clinic, Cleveland, United States;
  2. 2 Department of Ophthalmology, Hadassah University Hospital Jerusalem, Israel;
  3. 3 Department of Ophthalmology, University of Padua, Padua, Italy;
  4. 4 St Erik’s Eye Hospital Karolinksa University, Stockholm, Sweden;
  5. 5 University Hospital, United Kingdom;
  6. 6 Cole Eye Institute, Cleveland Clinic Foundation, United States
  1. To whom correspondence should be addressed. E-mail: singha{at}ccf.org

Abstract

Ocular surface squamous neoplasia (OSSN) is a spectrum of malignant neoplasia of the conjunctiva, limbus and cornea that includes epithelial dysplasia, carcinoma-in-situ and invasive squamous cell carcinoma (SCC). Numerous factors including genetic predisposition, UV light exposure, smoking, immunosuppression, and HPV infection have been identified as risk factors.[1]

Statistics from Altmetric.com

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles